{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:19:57Z","timestamp":1788265197541,"version":"build-2803163510"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fujian Province Natural Science Foundation of China","award":["2023J11475"],"award-info":[{"award-number":["2023J11475"]}]},{"name":"Fujian Province Natural Science Foundation of China","award":["2024J011240"],"award-info":[{"award-number":["2024J011240"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-024-02599-1","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T02:25:24Z","timestamp":1734920724000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A predictive model for functional cure in chronic HBV patients treated with pegylated interferon alpha: a comparative study of multiple algorithms based on clinical data"],"prefix":"10.1186","volume":"21","author":[{"given":"Ya-mei","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-yan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"2599_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ijid.2022.09.003","volume":"124","author":"Z Marjenberg","year":"2022","unstructured":"Marjenberg Z, Wright C, Pooley N, Cheung KW, Shimakawa Y, Vargas-Zambrano JC, et al. Hepatitis B surface antigen prevalence and the rates of mother-to-child transmission of hepatitis B virus after the introduction of infant vaccination programs in South East Asia and Western Pacific regions: a systematic review. Int J Infect Dis. 2022;124:65\u201375.","journal-title":"Int J Infect Dis"},{"key":"2599_CR2","doi-asserted-by":"publisher","first-page":"18036","DOI":"10.1038\/nrdp.2018.36","volume":"4","author":"B Hepatitis","year":"2018","unstructured":"Hepatitis B. Virus infection. Nat Rev Dis Primers. 2018;4:18036.","journal-title":"Nat Rev Dis Primers"},{"issue":"10381","key":"2599_CR3","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","volume":"401","author":"WJ Jeng","year":"2023","unstructured":"Jeng WJ, Papatheodoridis GV, Lok ASF. Hepat B Lancet. 2023;401(10381):1039\u201352.","journal-title":"Hepat B Lancet"},{"issue":"2","key":"2599_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/cid\/ciaa013","volume":"72","author":"MS Farag","year":"2021","unstructured":"Farag MS, van Campenhout MJH, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, et al. Hepatitis B Virus RNA as early predictor for response to Pegylated Interferon Alpha in HBeAg-Negative chronic Hepatitis B. Clin Infect Dis. 2021;72(2):202\u201311.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2599_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/hep.25937","volume":"57","author":"CL Lai","year":"2013","unstructured":"Lai CL, Yuen MF. Prevention of Hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2013;57(1):399\u2013408.","journal-title":"Hepatology"},{"issue":"4","key":"2599_CR6","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","volume":"143","author":"C Boni","year":"2012","unstructured":"Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, Schivazappa S, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology. 2012;143(4):963\u201373. e9.","journal-title":"Gastroenterology"},{"issue":"3","key":"2599_CR7","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jhep.2018.05.004","volume":"69","author":"F Rinker","year":"2018","unstructured":"Rinker F, Zimmer CL, Honer Zu Siederdissen C, Manns MP, Kraft ARM, Wedemeyer H, et al. Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J Hepatol. 2018;69(3):584\u201393.","journal-title":"J Hepatol"},{"issue":"6","key":"2599_CR8","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1007\/s12072-022-10411-x","volume":"16","author":"YC Hsu","year":"2022","unstructured":"Hsu YC, Jun DW, Peng CY, Yeh ML, Trinh H, Wong GL, et al. Effectiveness of entecavir vs tenofovir disoproxil fumarate for functional cure of chronic hepatitis B in an international cohort. Hepatol Int. 2022;16(6):1297\u2013307.","journal-title":"Hepatol Int"},{"issue":"8","key":"2599_CR9","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","volume":"63","author":"G-A Kim","year":"2014","unstructured":"Kim G-A, Lim Y-S, An J, Lee D, Shim JH, Kim KM, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63(8):1325\u201332.","journal-title":"Gut"},{"issue":"8","key":"2599_CR10","first-page":"1629","volume":"71","author":"SAL Hall","year":"2022","unstructured":"Hall SAL, Vogrin S, Wawryk O, Burns GS, Visvanathan K, Sundararajan V, et al. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis. Gut. 2022;71(8):1629\u201341.","journal-title":"Gut"},{"issue":"4","key":"2599_CR11","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/hep.23844","volume":"52","author":"MJ Sonneveld","year":"2010","unstructured":"Sonneveld MJ, Rijckborst V, Boucher CA, Hansen BE, Janssen HL. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology. 2010;52(4):1251\u20137.","journal-title":"Hepatology"},{"issue":"9","key":"2599_CR12","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.cgh.2020.09.004","volume":"19","author":"HSJ Choi","year":"2021","unstructured":"Choi HSJ, van Campenhout MJH, van Vuuren AJ, Krassenburg LAP, Sonneveld MJ, de Knegt RJ, et al. Ultra-long-term follow-up of Interferon Alfa treatment for HBeAg-Positive chronic Hepatitis B Virus infection. Clin Gastroenterol Hepatol. 2021;19(9):1933\u2013e401.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2599_CR13","doi-asserted-by":"publisher","first-page":"105782","DOI":"10.1016\/j.antiviral.2023.105782","volume":"221","author":"Q Zhao","year":"2024","unstructured":"Zhao Q, Liu H, Tang L, Wang F, Tolufashe G, Chang J, et al. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy. Antiviral Res. 2024;221:105782.","journal-title":"Antiviral Res"},{"issue":"17","key":"2599_CR14","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jama.2018.3795","volume":"319","author":"LSY Tang","year":"2018","unstructured":"Tang LSY, Covert E, Wilson E, Kottilil S, Chronic Hepatitis B, Infection. Rev JAMA. 2018;319(17):1802\u201313.","journal-title":"Rev JAMA"},{"issue":"12","key":"2599_CR15","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1111\/jvh.13613","volume":"28","author":"HSJ Choi","year":"2021","unstructured":"Choi HSJ, Sonneveld MJ, Farag MS, Brouwer WP, Brakenhoff SM, Hirode G, et al. Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection. J Viral Hepatitis. 2021;28(12):1729\u201337.","journal-title":"J Viral Hepatitis"},{"key":"2599_CR16","doi-asserted-by":"crossref","unstructured":"Shang H, Hu Y, Guo H, Lai R, Fu Y, Xu S et al. Using machine learning models to predict HBeAg seroconversion in CHB patients receiving pegylated interferon-\u03b1 monotherapy. J Clin Lab Anal. 2022;36(11).","DOI":"10.1002\/jcla.24667"},{"issue":"1","key":"2599_CR17","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1186\/s12879-021-06883-1","volume":"21","author":"YW Zhong","year":"2021","unstructured":"Zhong YW, Shi YM, Chu F, Liu J, Shi C, Xu JJ, et al. Prediction for HBsAg seroconversion in children with chronic hepatitis B. BMC Infect Dis. 2021;21(1):1211.","journal-title":"BMC Infect Dis"},{"key":"2599_CR18","doi-asserted-by":"crossref","unstructured":"Luo M, Zhang L, Yang C, Zhou B, Hou J, Jiang DK. CXCL13 variant predicts pegylated-interferon \u03b1 treatment response in HBeAg\u2010positive chronic hepatitis B patients. J Med Virol. 2023;95(7).","DOI":"10.1002\/jmv.28963"},{"key":"2599_CR19","doi-asserted-by":"crossref","unstructured":"Tian X, Chong Y, Huang Y, Guo P, Li M, Zhang W et al. Using Machine Learning Algorithms to Predict Hepatitis B Surface Antigen Seroclearance. Computational and Mathematical Methods in Medicine. 2019;2019:1\u20137.","DOI":"10.1155\/2019\/6915850"},{"issue":"1","key":"2599_CR20","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/hep.26180","volume":"58","author":"T Hosaka","year":"2013","unstructured":"Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, et al. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection. Hepatology (Baltimore MD). 2013;58(1):98\u2013107.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"4","key":"2599_CR21","first-page":"1560","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology (Baltimore. Md). 2018;67(4):1560\u201399.","journal-title":"Md)"},{"issue":"15","key":"2599_CR22","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1056\/NEJMoa033364","volume":"351","author":"YF Liaw","year":"2004","unstructured":"Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521\u201331.","journal-title":"N Engl J Med"},{"issue":"12","key":"2599_CR23","doi-asserted-by":"publisher","first-page":"e18440","DOI":"10.1111\/jcmm.18440","volume":"28","author":"RR Zhou","year":"2024","unstructured":"Zhou RR, Song YH, Xu CY, Zhang YY, Wu XW, Zhang L, et al. Altered counts and mitochondrial mass of peripheral blood leucocytes in patients with chronic hepatitis B virus infection. J Cell Mol Med. 2024;28(12):e18440.","journal-title":"J Cell Mol Med"},{"issue":"10","key":"2599_CR24","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMoa051285","volume":"354","author":"TT Chang","year":"2006","unstructured":"Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006;354(10):1001\u201310.","journal-title":"N Engl J Med"},{"issue":"23","key":"2599_CR25","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1056\/NEJMoa0802878","volume":"359","author":"P Marcellin","year":"2008","unstructured":"Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008;359(23):2442\u201355.","journal-title":"N Engl J Med"},{"issue":"26","key":"2599_CR26","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1056\/NEJMoa043470","volume":"352","author":"GK Lau","year":"2005","unstructured":"Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005;352(26):2682\u201395.","journal-title":"N Engl J Med"},{"issue":"3","key":"2599_CR27","doi-asserted-by":"publisher","first-page":"e175","DOI":"10.1016\/S2352-3026(20)30373-2","volume":"8","author":"T Barbui","year":"2021","unstructured":"Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. Lancet Haematol. 2021;8(3):e175\u201384.","journal-title":"Lancet Haematol"},{"issue":"7","key":"2599_CR28","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1053\/j.gastro.2009.03.006","volume":"136","author":"P Marcellin","year":"2009","unstructured":"Marcellin P, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology. 2009;136(7):2169\u2013e791.","journal-title":"Gastroenterology"},{"issue":"13","key":"2599_CR29","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3748\/wjg.v26.i13.1525","volume":"26","author":"FP Wu","year":"2020","unstructured":"Wu FP, Yang Y, Li M, Liu YX, Li YP, Wang WJ, et al. Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen = 1500 IU\/mL: an observational study<\/at. World J Gastroenterol. 2020;26(13):1525\u201339.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2599_CR30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12985-021-01589-x","volume":"18","author":"A Song","year":"2021","unstructured":"Song A, Lin X, Chen X. Functional cure for chronic hepatitis B: accessibility, durability, and prognosis. Virol J. 2021;18(1):114.","journal-title":"Virol J"},{"issue":"1","key":"2599_CR31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jhep.2022.01.021","volume":"77","author":"D Huang","year":"2022","unstructured":"Huang D, Wu D, Wang P, Wang Y, Yuan W, Hu D, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol. 2022;77(1):42\u201354.","journal-title":"J Hepatol"},{"key":"2599_CR32","doi-asserted-by":"publisher","first-page":"1332232","DOI":"10.3389\/fcimb.2023.1332232","volume":"13","author":"C Wen","year":"2023","unstructured":"Wen C, Wang Y, Tian H, Lei Y, Wang Z, Cai D, et al. Clinical cure induced by pegylated interferon alpha-2b in the advantaged population of chronic hepatitis B virus infection: a retrospective cohort study. Front Cell Infect Microbiol. 2023;13:1332232.","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"2599_CR33","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.jhep.2016.12.024","volume":"66","author":"F Lebosse","year":"2017","unstructured":"Lebosse F, Testoni B, Fresquet J, Facchetti F, Galmozzi E, Fournier M, et al. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. J Hepatol. 2017;66(5):897\u2013909.","journal-title":"J Hepatol"},{"key":"2599_CR34","doi-asserted-by":"crossref","unstructured":"Zheng B, Yu Y, Pan Z, Feng Y, Zhao H, Han Q et al. HBsAg dampened STING Associated activation of NK cells in HBeAg-Negative CHB patients. Int J Mol Sci. 2021;22(14).","DOI":"10.3390\/ijms22147643"},{"issue":"2","key":"2599_CR35","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/j.1365-2567.2008.02896.x","volume":"126","author":"ML Op den Brouw","year":"2009","unstructured":"Op den Brouw ML, Binda RS, van Roosmalen MH, Protzer U, Janssen HL, van der Molen RG, et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Immunology. 2009;126(2):280\u20139.","journal-title":"Immunology"},{"key":"2599_CR36","doi-asserted-by":"publisher","first-page":"1426960","DOI":"10.3389\/fcimb.2024.1426960","volume":"14","author":"W Zhong","year":"2024","unstructured":"Zhong W, Yan L, Zhu Y, Shi L, He Y, Chen T, et al. A high functional cure rate was induced by pegylated interferon alpha-2b treatment in postpartum hepatitis B e antigen-negative women with chronic hepatitis B virus infection: an exploratory study. Front Cell Infect Microbiol. 2024;14:1426960.","journal-title":"Front Cell Infect Microbiol"},{"issue":"1","key":"2599_CR37","doi-asserted-by":"publisher","first-page":"2404965","DOI":"10.1080\/21505594.2024.2404965","volume":"15","author":"J Wang","year":"2024","unstructured":"Wang J, Zhang Z, Zhu L, Zhang Q, Zhang S, Pan Y, et al. Association of Hepatitis B core antibody level and hepatitis B surface antigen clearance in HBeAg-negative patients with chronic hepatitis B. Virulence. 2024;15(1):2404965.","journal-title":"Virulence"},{"issue":"4","key":"2599_CR38","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/17474124.2021.1866985","volume":"15","author":"M-L Yeh","year":"2020","unstructured":"Yeh M-L, Huang J-F, Yu M-L, Chuang W-L. Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa. Expert Rev Gastroenterol Hepatol. 2020;15(4):427\u201335.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2599_CR39","doi-asserted-by":"crossref","unstructured":"Chemin I, Wei L, Wedemeyer H, Liaw Y-F, Chan HL-Y, Piratvisuth T et al. No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B. Plos One. 2018;13(7).","DOI":"10.1371\/journal.pone.0199198"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02599-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-024-02599-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-024-02599-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T03:05:55Z","timestamp":1734923155000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-024-02599-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2599"],"URL":"https:\/\/doi.org\/10.1186\/s12985-024-02599-1","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical guidelines of the Declaration of Helsinki and Istanbul. The study was approved by the Human Ethics Committee of Mengchao Hepatobiliary Hospital (No. 2024-081-01).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the fnal manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"333"}}